Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Cash & Equivalents (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of Cash & Equivalents data on record, last reported at $183.6 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 93.68% year-over-year to $183.6 million; the TTM value through Dec 2025 reached $183.6 million, up 93.68%, while the annual FY2025 figure was $183.6 million, 93.68% up from the prior year.
  • Cash & Equivalents reached $183.6 million in Q4 2025 per TARS's latest filing, up from $112.7 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $245.4 million in Q2 2022 and bottomed at $66.0 million in Q1 2023.
  • Average Cash & Equivalents over 5 years is $159.4 million, with a median of $175.4 million recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: soared 232.55% in 2021, then tumbled 62.29% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $171.3 million in 2021, then plummeted by 58.17% to $71.7 million in 2022, then skyrocketed by 213.91% to $224.9 million in 2023, then plummeted by 57.85% to $94.8 million in 2024, then surged by 93.68% to $183.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $183.6 million in Q4 2025, $112.7 million in Q3 2025, and $96.6 million in Q2 2025.